Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synsam ABCHIX:SYNSAS 85 Debt-to-EBITDA is 2.17 as of Mar. 2026, which is 23% below its 10-year median of 2.80. GuruFocus rates CHIX:SYNSAS with a GF Score™ of 85/100 and a GF Value™ of kr64.34. The stock has 1 warning sign investors should review. Among 469 Medical Devices & Instruments companies, Synsam AB ranks worse than 57.14% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Synsam AB's Debt-to-EBITDA or its related term are showing as below:
CHIX:SYNSAs'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.96 Med: 2.8 Max: 12.35
Current: 1.96
During the past 8 years, the highest Debt-to-EBITDA Ratio of Synsam AB was 12.35. The lowest was 1.96. And the median was 2.80.
CHIX:SYNSAs's Debt-to-EBITDA is ranked worse than 57.14% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs CHIX:SYNSAs: 1.96
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Synsam AB Debt-to-EBITDA Related Terms
Synsam AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Synsam AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SYNSAS vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Synsam AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synsam AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synsam AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Synsam AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Synsam AB (CHIX:SYNSAS) has a Debt-to-EBITDA of 2.17 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synsam AB. This is 23% below median its historical median of 2.80. Over the past decade, Synsam AB's Debt-to-EBITDA has ranged from 1.96 to 12.35. According to the industry distribution chart, Synsam AB ranks #268 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 57.1%.
Is Synsam AB's Debt-to-EBITDA too high?
Synsam AB's current Debt-to-EBITDA of 2.17 is 23% below median its 10-year median of 2.80. Over the past 10 years, this metric has ranged from a low of 1.96 to a high of 12.35. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Synsam AB's value of 2.17 is 35.6% above this industry median. Based on the distribution chart, Synsam AB ranks #268 out of 469 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Synsam AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Synsam AB's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Synsam AB ranks #268 out of 469 companies for Debt-to-EBITDA. This places Synsam AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. Synsam AB's value of 2.17 is 35.6% above this benchmark. Historically, Synsam AB's own Debt-to-EBITDA has ranged from 1.96 to 12.35 over the past decade. While the company's 10-year median is 2.80 vs. the industry median of 1.60, Synsam AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synsam AB's current Debt-to-EBITDA of 2.17 is 35.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Synsam AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synsam AB's current Debt-to-EBITDA is 2.17, which is 23% below median its own 10-year median of 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synsam AB stock overvalued right now?
Synsam AB (CHIX:SYNSAS) has a current Debt-to-EBITDA of 2.17. The stock's GF Value™ is kr64.34, compared to a current price of kr59.80 — trading 7.1% below its estimated fair value. The current Debt-to-EBITDA is 2.17, which is 23% below median its 10-year median of 2.80 and 35.6% above the Medical Devices & Instruments industry median of 1.60. Synsam AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Synsam AB (CHIX:SYNSAS), the current Debt-to-EBITDA is 2.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synsam AB (CHIX:SYNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Synsam AB stock appears to be undervalued.
The current stock price of kr59.80 is trading 7.1% below its estimated GF Value™ of kr64.34.
Key valuation signals for CHIX:SYNSAS:
Debt-to-EBITDA: 2.17 (23% below median its 10-year median of 2.80)
GF Value™: kr64.34 vs. price of kr59.80 (7.1% below fair value)
Industry Position: 35.6% above the Medical Devices & Instruments median (#268 of 469)
No single metric tells the full story. See the CHIX:SYNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synsam AB is a lifestyle company in optics and eye health in the Nordic region. The company offers various products and services in physical and digital stores, such as eye examinations, spectacles, sunglasses, sports spectacles, contact lenses, and accessories in optical retail, as well as spectacles subscriptions and related services under the name Synsam Lifestyle. Its stores are operated under the Synsam brand in Sweden, Norway, and Finland, and under the Profil Optik brand in Denmark and Iceland. The company comprises four segments: Sweden, which generates key revenue, Denmark, Norway, and Finland.
85GF Score
Get the complete analysis for CHIX:SYNSAS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SYNSAS has been successfully added to your 
